Join the Canadian researchers as they take apart the recent decision by Avrobio to cancel their program for the development of a gene therapy for Fabry patients. This decision was made based on a number of considerations, read more here: https://www.socialpharmaceuticalinnovation.org/post/a-gene-therapy-for-fabry-patients-a-derelict-dream Please share any thoughts you have on this with us below!

In this blog post, our Canadian researchers discuss the value of big data in the use of federated data systems in the rare disease space. To read more about this subject: https://www.socialpharmaceuticalinnovation.org/post/federated-data-systems-filling-canada-s-health-data-gap-going-big-with-big-data Share your thoughts on this knowledge production network below!

In this blog post, our Canadian team discusses the approval of Nexviayme for Pompe Disease in the Canadian context. https://www.socialpharmaceuticalinnovation.org/post/nexviayme-approved-for-pompe-disease-by-health-canada